Role of CDX2 Marker in Patients with Colorectal Cancer

Abstract

CDX2 has been proposed as a tumor suppressor in colon cancer, CDX2 gene is often amplified in colon cancer, there is a lineage survival oncogene function in some tumors, the role of CDX2 protein during CRC development remains debatable. The aim of this study investigate the effect of low CDX2 expression on overall survival (OS) for prognosis of CRC patients and estimate of therapeutic activity of CDX2 expression in predictive of chemotherapy respond. This study done in the Middle Euphrates Unit for Cancer Research, Faculty of Medicine, University of Kufa in Al-Najaf province. This study was carried out on sixty-three cases of CRC in the form of available paraffin blocks who underwent surgical resection between 2015 and 2020. Thirty_ seven blocks of normal non tumoral colorectal tissue collected randomly from archives of two private laboratories during collection of malignant tissue blocks. Nuclear low expression of CDX2 in control and patient groups were 0(0.00%) and 30 (47.6%), while high expression of this protein was 37 (100%) and 33(52.4%) in control and patient groups respectively. OS was longer in patients with low CDX2 protein expression who intake adjuvant chemotherapy (71.33%) with mean survival (24.75±2.81 month) than patients were not intake adjuvant chemotherapy (53.71%) with mean survival (15.227±1.66 month). CDX2 expression regarded as diagnostic marker for non-mucinous CRC. High of CDX2 expression can be used as an independent good prognostic biomarker to predict longer survival of patients with CRC.